Vincristine is a vinca alkaloid used to treat acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis. Vincristine is an antitumor vinca alkaloid isolated from Vinca Rosea.
- Mechanism
- Curator reviewed
The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca2+-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.
- Primary indication
- Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma.Curator reviewed · 20 structured indications
- Formula / weight
- C46H56N4O10 · 824.972 g/mol (avg)
- First approval
- Canada, 2009 · United States, 2000
- Also known as
- 22-Oxovincaleukoblastin · 22-Oxovincaleukoblastine · Leurocristine
- Code names
- L 37231 · NSC 67574
- Brand names
Resolves to
OGWKCGZFUXNPDA-CFWMRBGOSA-NSMILES[H][C@@]12N3CC[C@@]11C4=C(C=C(OC)C(=C4)[C@]4(C[C@H]5C[N@](C[C@](O)(CC)C5)CCC5=C4NC4=CC=CC=C54)C(=O)OC)N(C=O)[C@@]1([H])[C@](O)([C@H](OC(C)=O)[C@]2(CC)C=CC3)C(=O)OCWhat you can answer from here — as of August 31, 2026
Which drugs share a target with Vincristine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account